Eli Lilly Corp. sell tamam
Start price
17.04.17
/
50%
€73.33
Target price
25.04.17
€67.20
Performance (%)
1.73%
End price
25.04.17
€74.60
Summary
This prediction ended on 25.04.17 with a price of €74.60. The SELL prediction by tamam shows the price for Eli Lilly Corp. slightly increased by 1.73% during the runtime of the prediction. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Eli Lilly Corp. | -0.248% | -0.248% | 75.167% | 343.399% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by tamam for this prediction
In the thread Eli Lilly Corp. diskutieren
tamam stimmt dem Sentiment von 'Sell' zu
Eli Lilly (NYSE:LLY) has received a Complete Response Letter (CRL) from the FDA regarding its New Drug
Application (NDA) seeking approval of JAK inhibitor baricitinib for the treatment of moderate-to-severe rheumatoid arthritis (RA). The FDA cited the need for more clinical data to support the optimum doses and additional data to further characterize the safety profile across treatment arms.
(Vom Mitglied beendet)
Stopped prediction by tamam for Eli Lilly Corp.
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€99.11
11.07.19
11.07.19
€160.75
04.11.21
04.11.21
136.20%
05.11.21
05.11.21
